The atherectomy devices market, by product type is categorised into directional atherectomy
systems, orbital atherectomy systems, photo-ablative (laser) atherectomy systems, rotational atherectomy systems, and others.
Based on product, the directional atherectomy
devices segment is expected to witness the highest growth during the forecast period.
Thus, debulking strategies with directional atherectomy
prior to DCB-treatment were demonstrated to further improve patency rates in recent trials (17).
Several interventional devices, including laser excimer atherectomy, directional atherectomy
, rotational atherectomy, and cutting balloon angioplasty, have been applied to prevent restenosis; however, the results have been discouraging.
and specialty balloons, while not evaluated in this study, are commonly used to debulk or predictably dilate calcified lesions, which may minimize the need for provisional stents.
Garcia et al., "One-year outcomes following directional atherectomy
of infrapopliteal artery lesions: subgroup results of the prospective, multicenter DEFINITIVE LE Trial," Journal of Endovascular Therapy, vol.
Lumivascular technology allows physicians, for the first time ever, to see from inside the artery during a directional atherectomy
procedure by using an imaging modality called optical coherence tomography, or OCT, which is displayed on the Lightbox console.
Lumivascular technology in the Pantheris catheter allows physicians, for the first time ever, to see from inside the artery during a directional atherectomy
procedure by using an imaging modality called optical coherence tomography, or OCT.
One method is directional atherectomy
, which can be employed, for example, by the TurboHawk Plaque Excision System by Coviden (Plymouth, MN).
has received CE Mark approval for Pantheris a system that combines directional atherectomy
capabilities with real-time intravascular visualization to remove plaque from blocked arteries.
A subgroup analysis from the DEFINITIVE LE study for directional atherectomy
of infrapopliteal lesions showed high technical success and 1-year primary patency rates of 84%.
Food and Drug Administration (FDA) 510(k) clearance for the HawkOne(TM) Directional Atherectomy
System in a new size for treating patients with peripheral artery disease (PAD).